Survodutide is a new weight loss medication manufactured by Zealand and Boehringer Ingelheim that is currently in its testing phases. Though there are many weight loss medicines dominating the market at the minute, Survodutide has a unique property that helps it stand out from it’s competitors.
What is MASH?
MASH, or Metabolic Dysfunction-associated Steatohepatitis is also known as NASH (Non-Alcoholic Steatohepatitis). This is related to an underlying metabolic issues, which has direct links to obesity or insulin resistance. MASH is a condition where excess fat accumulates in the liver, leading to inflammation and potential damage. It can look like alcoholic hepatisis, but can come around due to metabolic issues rather than alcohol abuse.
What is Survodutide?
Survodutide is a glucagon receptor dual agonist that activates the GLP-1 receptors and glucagon receptors responsible for manipulation of metabolic function. GLP-1 receptor agonists are incredibly common in the weight loss world, with the likes of Wegovy and Mounjaro’s active ingredients both having this mechanism of action. However, with Survodutide’s specificity on glucagon, it makes it applicable for treatment in not just chronic obesity, but also Type 2 diabetes and more specifically NASH in adults and stages 1 to 3 of liver fibrosis.
How has it helped patients with MASH?
In Phase II of clinical trials, Survodutide has shown 83% of adults treated achieved incredible results in liver disease caused by MASH, as well as significant improvements with fibrosis. As a glucagon/GLP-1 receptor dual agonist demonstrating usefulness in both obesity and aiding people suffering from MASH suggests important clinical benefits in the cardiovascular, renal and metabolic scope. All helping to contribute to a healthier you.
